Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (HKG:2566)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
7.10
-0.01 (-0.14%)
At close: Apr 17, 2026

HKG:2566 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
1,3061,3691,2871,1251,307
Revenue Growth (YoY)
-4.59%6.35%14.39%-13.91%-
Cost of Revenue
252.24287.51296.74271.14356.84
Gross Profit
1,0541,082990.67854.26950.41
Selling, General & Admin
785.77808.38723.62649.02686.08
Research & Development
123.66108.9127.76158.31132.63
Other Operating Expenses
3.337.361.871.021.42
Operating Expenses
912.76924.63853.25808.35820.13
Operating Income
141.3157.05137.4245.91130.28
Interest Expense
-5.66-7.15-9.39-9.04-9.72
Interest & Investment Income
10.521.280.280.180.32
Currency Exchange Gain (Loss)
0.221.080.210.2-0.12
Other Non Operating Income (Expenses)
15.1416.366.4114.166.77
Pretax Income
161.52168.63134.9351.42127.54
Income Tax Expense
23.1230.0315.16-8.458.12
Net Income
138.41138.6119.7859.87119.41
Net Income to Common
138.41138.6119.7859.87119.41
Net Income Growth
-0.14%15.72%100.07%-49.87%-
Shares Outstanding (Basic)
245204200200200
Shares Outstanding (Diluted)
245204200200200
Shares Change (YoY)
20.16%2.11%---
EPS (Basic)
0.560.680.600.300.60
EPS (Diluted)
0.560.680.600.300.60
EPS Growth
-16.89%13.32%100.07%-49.87%-
Free Cash Flow
-79.69114.66-0.7413.59
Free Cash Flow Per Share
-0.390.57-0.000.07
Dividend Per Share
0.0570.056---
Dividend Growth
1.79%----
Gross Margin
80.69%79.00%76.95%75.91%72.70%
Operating Margin
10.82%11.47%10.67%4.08%9.97%
Profit Margin
10.60%10.12%9.30%5.32%9.13%
Free Cash Flow Margin
-5.82%8.91%-0.07%1.04%
EBITDA
176.69192.44172.3581.18154.06
EBITDA Margin
13.53%14.06%13.39%7.21%11.79%
D&A For EBITDA
35.3935.3934.9335.2723.78
EBIT
141.3157.05137.4245.91130.28
EBIT Margin
10.82%11.47%10.67%4.08%9.97%
Effective Tax Rate
14.31%17.81%11.23%-6.37%
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.